A recent federal audit of Medicaid payments to autism therapy providers in Indiana has revealed alarming findings. The audit, conducted by the Department of Health and Human Services Office of Inspector General, found that all of the client records inspected had payments that were either improper or suspected to be.
The audit specifically focused on payments made to Indiana providers for performing applied behavior analysis (ABA), a commonly used therapy for managing autism symptoms. This audit in Indiana is the first of nine planned audits by the agency into state Medicaid payments for ABA therapy.
The most striking finding of the report is that Indiana made at least $56.6 million in improper Medicaid payments, as well as $76.7 million in potentially improper payments for ABA therapy in 2019 and 2020. This amounts to at least $133 million in estimated improper or potentially improper payments. However, the issue goes beyond just financial losses. The audit also uncovered that some therapy providers were not properly trained or certified.
The implications of these findings are significant. Improper payments not only result in financial losses for the Medicaid program but also raise concerns about the quality of care being provided to individuals with autism. Without proper training and certification, therapy providers may not be equipped to deliver effective and evidence-based treatments.
It is crucial for state Medicaid programs to ensure that payments are made accurately and that providers meet the necessary qualifications to deliver high-quality care. This audit serves as a reminder of the importance of oversight and accountability in healthcare services, especially for vulnerable populations like individuals with autism.
For more in-depth analysis and coverage of this story, subscribers can access the full article on STAT+, which provides daily market-moving biopharma analysis and exclusive content. Subscribing to STAT+ will unlock access to this article and other valuable resources for staying informed about the latest developments in healthcare and biopharma.
